letetresgene autoleucel (GSK3377794) / Adaptimmune 
Welcome,         Profile    Billing    Logout  
 13 Diseases   3 Trials   3 Trials   119 News 


123»
  • ||||||||||  letetresgene autoleucel (GSK3377794) / Adaptimmune
    Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS) (Hall C) -  Oct 6, 2022 - Abstract #SITC2022SITC_928;    
    P2
    Preliminary gene expression data from the tumors collected at baseline showed enrichment of metabolic pathways in responders and epithelial–mesenchymal transition and fibroblast activation in non-responders. Conclusions These data suggest that higher lete-cel persistence and the association of lete-cel expansion with cytokine upregulation post-infusion, as well as tumor-intrinsic transcriptional features, may have a role in lete-cel response in patients with advanced MRCLS.
  • ||||||||||  letetresgene autoleucel (GSK3377794) / Adaptimmune, LYL331 / Lyell Immunopharma
    Increased potency and functional persistence in vitro of a next-generation NY-ESO-1-specific TCR therapy incorporating Gen-RTM genetic reprogramming technology (Hall C) -  Oct 6, 2022 - Abstract #SITC2022SITC_569;    
    Conclusions In addition to supporting the hypothesis that genetic reprogramming with Gen-R technology can delay the onset of exhaustion and improve the long-term durable functions of LYL331, these data show that c-Jun overexpression can provide immediate benefits to the NY-ESO-1-specific TCR therapy during primary stimulation in vitro . Based on these promising pre-clinical data, LYL331 may have the potential to improve clinical responses in patients with solid tumor malignancies.
  • ||||||||||  NY-ESO-1 TCR / Gilead
    Biomarker, Journal, IO biomarker:  Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma. (Pubmed Central) -  Sep 18, 2022   
    P1
    Analysis of tumor samples post-treatment illustrates lete-cel infiltration and a decrease in expression of macrophage genes, suggesting remodeling of the tumor microenvironment. Here we report potential predictive and pharmacodynamic markers of lete-cel response that may inform LDR, cell dose, and strategies to enhance anticancer efficacy.
  • ||||||||||  GSK3845097 / GSK, letetresgene autoleucel (GSK3377794) / GSK, ADP-A2M10 / Adaptimmune
    Journal:  Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β. (Pubmed Central) -  Jan 12, 2022   
    In this article, we show that exogenous TGF-β inhibited in vitro proliferation and effector functions of human T cells expressing these first-generation high-affinity TCRs, whereas inhibition was reduced or abolished in the case of second-generation TCRs coexpressed with dnTGFβRII (e.g., GSK3845097)...As an example, immunohistochemistry/RNAscope identified TGF-β-positive cells close to T cells in tumor nests and stroma, which had low frequencies of cells expressing IFN-γ in a non-small cell lung cancer setting. Coexpression of dnTGFβRII may therefore improve the efficacy of TCR-transduced T cells.
  • ||||||||||  letetresgene autoleucel (GSK3377794) / Adaptimmune
    Phase classification, Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  KEYNOTE-487: Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma (clinicaltrials.gov) -  Feb 25, 2021   
    P1,  N=6, Terminated, 
    The substudies are open and recruiting. Phase classification: P2 --> P1 | N=20 --> 6 | Trial completion date: Jan 2023 --> Nov 2020 | Recruiting --> Terminated | Trial primary completion date: Apr 2021 --> Jul 2020; The study was terminated following an internal review of the company's research and development portfolio